Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06663891

Chronic Anergic Depression IDentification - Magnetic Resonance Imaging Exploration in the Elderly of Traits Related to Onset

Depression in the elderly, or "late life depression" (LLD), is often considered to be homogeneous, legitimizing standardized treatment. Yet the literature suggests that there are different forms of LLD, with different pathophysiology, course and treatment.

Our experience has led us to identify an "anergic" form, marked by adynamia and anhedonia (anergic depression, AnD). Highly represented among LLDs, it readily resists the usual antidepressants, so that its course is often chronic. Thanks to the "Chronic Anergic Depression Open Trial", the investigators were able to show that AnD responds to dopaminergic (DA) molecules. Therefore the invastigators hypothesized a pathophysiology linked to dysfunction of the mesolimbic DA system.

However, not all patients would present the same form: two subgroups could be isolated, each contributing equally. The first corresponds to patients for whom the episode is a recurrence, the so-called "early onset depression" (EOD). The first episode occurs at 34 ±16 years of age and is frequently associated with a personality disorder (73%). The index episode usually lasts 6 ±3 years and is typically associated with anxiety (96%).

The second group corresponds to the onset of primary depression after the age of 60, known as "late onset depression" (LOD). The index episode occurs at around 71 ±6 years of age, in people with no premorbid personality disorders. The episode is shorter (3 ±1 years) and anxiety is frequent (75%) but less marked. These patients showed a high propensity for a course compatible with synucleinopathies, but often less rapid than that of the classic forms of these diseases.

The investigators hypothesize that within AnD, EOD and LOD present different pathophysiologies, and that this difference is observable on functional magnetic resonance imaging (MRI): LOD patients should present a greater reduction in functional connectivity in the mesolimbic system. The investigators make the subsidiary hypothesis that LODs also show a structural alteration observable with other types of MRI measurements, i.e. multiparametric imaging.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Late Life Depression Lethargy Nervous System Diseases Neurobehavioral Manifestations Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

60 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient aged 60 (inclusive) to 90 years (exclusive)
  • Patient presenting with active or remitted anergic depression according to the operational criteria of the "Chronic Anergic Depression Open Trial" (1) confirmed by two psychiatrists involved in the study:
  • Early Onset Depression (EOD) group: with at least one history of depression before age 60
  • Late Onset Depression (LOD) group: no history of depression before age 60
  • Patient able to understand the objectives/risks of the research and give informed consent
  • Patient affiliated to a health insurance social protection scheme, beneficiary or dependent

Exclusion criteria

  • Contraindication to an MRI scan (including claustrophobia)*
  • Psychiatric or organic comorbidity that may interfere with the interpretation of results (e.g. neurovascular disease, psychotic disorder, proven neurodegenerative disease)
  • Concomitant treatment that may interfere with the interpretation of results (e.g. interferons, corticosteroids)
  • Patient in exclusion period (from a previous or current study)
  • Current protective measure (curatorship, guardianship)
  • Patient under legal protection * presence of non-removable ferromagnetic foreign body, prosthesis, pacemaker, defibrillator, neurostimulation device, medications delivered by an implanted pump, vascular clip or stent, heart valve or ventricular shunt, implanted device incompatible with 3 Tesla MRI exam, claustrophobia, epilepsy

Treatment and study plan

Functional MRI with EEG per MRI

Other

2 MRI examinations will be carried out on a Siemens Vida® MRI ( Siemens®, Erlangen, Germany) 3 Tesla. During this study, no MRI examination requires the injection of a contrast agent.

Different sequences, according to several acquisition modalities, will be performed during each MRI. The structural sequences (T1 and T2, MPRAGE) will highlight any lesions in the form of atrophies and/or vascular lesions in the participants, also subject to inter-individual differences. The examination will also involve a quantitative multiparametric acquisition with 8 modalities (R1, R2, Radial and Axial Diffusion in Diffusion Tensor, dispersion, orientation and density index of neurites by NODDI, the Macromolecular Proton Fraction, measurement of magnetic susceptibility and R2*) to characterize tissue properties. Functional imaging (in resting state, during film viewing and performance of cognitive tasks in ASL, BOLD and multiband) will allow analysis of the primary endpoint - functional connectivity,

Primary outcomes

  1. VTA - mesolimbic system functional connectivity

    Time frame: Day 1

    Functional connectivity, observed at the subpopulation level, between the ventral tegmental area (VTA) and regions of the mesolimbic system (i.e.: ventral striatum and pallidum, amygdala, and subgenual anterior cingulate [with separate analysis of Brodmann area 25] and ventromedial prefrontal cortex), obtained by ROI to ROI analysis.

Secondary outcomes

  1. Perfusion of the mesolimbic system

    Time frame: Day 1

    Mean cerebral perfusion rates measured by arterial spin labeling (ASL) in regions of interest (i.e.: ventral tegmental area, ventral striatum and pallidum, amygdala, and subgenual anterior cingulate [with separate analysis of Brodmann area 25] and ventromedial prefrontal cortex).

  2. Perfusion of the mesolimbic system

    Time frame: Day 13

    Mean cerebral perfusion rates measured by arterial spin labeling (ASL) in regions of interest (i.e.: ventral tegmental area, ventral striatum and pallidum, amygdala, and subgenual anterior cingulate [with separate analysis of Brodmann area 25] and ventromedial prefrontal cortex).

Other outcomes

  1. Quantitative parameters measured in multiparametric MRI in the ventral tegmental area

    Time frame: Day 1

    R1

  2. Quantitative parameters measured in multiparametric MRI in the ventral tegmental area

    Time frame: Day 13

    R1

  3. Θ / β powers ratio

    Time frame: Day 1

    Frequency and maximum intensity of fluctuations in the ratio between the powers in θ and β bands. This analysis aims to allow the localization of the regions associated with fluctuations in vigilance during acquisition. This localization will be allowed by a methodology and analysis parameters already published by our team. The MRI localization maps obtained at the subpopulation level will be compared.

  4. Θ / β powers ratio

    Time frame: Day 13

    Frequency and maximum intensity of fluctuations in the ratio between the powers in θ and β bands. This analysis aims to allow the localization of the regions associated with fluctuations in vigilance during acquisition. This localization will be allowed by a methodology and analysis parameters already published by our team. The MRI localization maps obtained at the subpopulation level will be compared.

  5. Mesolimbic system - whole brain functional connectivity

    Time frame: Day 1

    Functional connectivity, observed at the subpopulation level, between regions of the mesolimbic system (as defined according to the primary outcome measure) and the rest of the brain, obtained by seed-to-voxel analysis.

    The seeds will be the regions of the mesolimbic system (i.e.: the ventral striatum and pallidum, the amygdala, the subgenual anterior cingulate cortex [with separate analysis of Brodmann area 25] and ventromedial prefrontal cortex and the substantia nigra). The analysis area will be the entire brain .

  6. Quantitative parameters measured in multiparametric MRI in the ventral tegmental area

    Time frame: Day 1

    Radial and Axial Diffusion in Diffusion Tensor

  7. Quantitative parameters measured in multiparametric MRI in the ventral tegmental area

    Time frame: Day 13

    R2

  8. Quantitative parameters measured in multiparametric MRI in the ventral tegmental area

    Time frame: Day 1

    R2

  9. Quantitative parameters measured in multiparametric MRI in the ventral tegmental area

    Time frame: Day 13

    Radial and Axial Diffusion in Diffusion Tensor

  10. Quantitative parameters measured in multiparametric MRI in the ventral tegmental area

    Time frame: Day 1

    Dispersion index

  11. Quantitative parameters measured in multiparametric MRI in the ventral tegmental area

    Time frame: Day 13

    Dispersion index

  12. Quantitative parameters measured in multiparametric MRI in the ventral tegmental area

    Time frame: Day 1

    Orientation and density of neurites by NODDI

  13. Quantitative parameters measured in multiparametric MRI in the ventral tegmental area

    Time frame: Day 13

    Orientation and density of neurites by NODDI

  14. Quantitative parameters measured in multiparametric MRI in the ventral tegmental area

    Time frame: Day 1

    Macromolecular Proton Fraction

  15. Quantitative parameters measured in multiparametric MRI in the ventral tegmental area

    Time frame: Day 13

    Macromolecular Proton Fraction

  16. Quantitative parameters measured in multiparametric MRI in the ventral tegmental area

    Time frame: Day 1

    Measurement of magnetic susceptibility and R2

  17. Quantitative parameters measured in multiparametric MRI in the ventral tegmental area

    Time frame: Day 13

    Measurement of magnetic susceptibility and R2

Study contacts

Contact information is provided by the study sponsor or research team.

Ludovic DORMEGNY-JEANJEAN Doctor

CONTACT

[email protected]

+33388116921

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Official study title

Identification of Trait Markers Differentiating Late-onset Depression from Early-onset Depression in Chronic Anergic Depression in the Elderly

Acronym: CAnD'ID-METRO

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Oct 29, 2024
Registry last updated
Oct 29, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.